Publication at First Faculty of Medicine |
2020
Abstract
Immunotherapy is effective across solid tumours, but only in part of the treated patients can achieve therapeutic response. It is most effective in the most immunogenic tumours, such as malignant melanomas, renal and lung carcinomas.
The limitation of immunotherapy is the lack of predictive biomarkers and immunomarkers, which are necessary to narrow the therapeutic throat in the patient selection. Application of immunotherapy requires a change in clinical thinking - it is not a choice of the best treatment modality, but a choice of (optimal) treatment for each patient.